FDA Fast Tracks Investigational Cystic Fibrosis Drug
SPL84, an antisense oligonucleotide treatment for cystic fibrosis patients with a specific mutation, gains FDA Fast Track designation.
Tag: SpliSense
FDA Fast Tracks Investigational Cystic Fibrosis Drug
SPL84, an antisense oligonucleotide treatment for cystic fibrosis patients with a specific mutation, gains FDA Fast Track designation.
Read More
SpliSense Gets FDA Nod for Phase 2 Trial for Investigational CF Treatment
The trial will test the efficacy of SpliSense’s inhaled antisense oligonucleotide drug as a potential treatment for the lungs of people with cystic fibrosis with a certain splicing mutation.
Read More
SpliSense Cystic Fibrosis Drug Undergoes Clinical Trials
The FDA has granted orphan drug designation to the SpliSense cystic fibrosis drug SPL84-23, an ASO (antisense oligonucleotide).
Read More